StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Morgan Stanley Downgrades bluebird bio (BLUE) to Underweight, 'commercialization will remain challenging'
November 8, 2021 5:11 AM
Morgan Stanley analyst Matthew Harrison downgraded bluebird bio (NASDAQ: BLUE) from Equalweight to Underweight with a price target of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Downgrades
Hot Comments
Hot Downgrades
Next Articles
Goldman Sachs Downgrades bluebird bio (BLUE) to Sell
November 8, 2021 7:38 AM
bluebird bio (BLUE) PT Lowered to $13 at Barclays
November 8, 2021 4:08 AM
bluebird bio (BLUE) Misses Q3 EPS by 56c
November 5, 2021 7:17 AM
Form 10-Q bluebird bio, Inc. For: Sep 30
November 5, 2021 7:15 AM
Form 8-K bluebird bio, Inc. For: Nov 05
November 5, 2021 7:09 AM
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
November 5, 2021 7:05 AM
bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
November 5, 2021 6:58 AM
bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
November 4, 2021 9:00 AM
Form 8-K bluebird bio, Inc. For: Nov 03
November 4, 2021 7:32 AM
bluebird bio Completes Planned Business Separation
November 4, 2021 7:00 AM
